MX2012007933A - Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. - Google Patents

Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.

Info

Publication number
MX2012007933A
MX2012007933A MX2012007933A MX2012007933A MX2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A
Authority
MX
Mexico
Prior art keywords
methods
topical transdermal
transdermal dexmedetomidine
dexmedetomidine compositions
compositions
Prior art date
Application number
MX2012007933A
Other languages
English (en)
Spanish (es)
Inventor
Geraldine A Henwood
Randall J Mack
Christopher T Sharr
John J Koleng Jr
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of MX2012007933A publication Critical patent/MX2012007933A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2012007933A 2010-01-08 2011-01-07 Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. MX2012007933A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29344010P 2010-01-08 2010-01-08
PCT/US2011/020462 WO2011085162A2 (en) 2010-01-08 2011-01-07 Topical transdermal dexmedetomidine compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2012007933A true MX2012007933A (es) 2012-08-15

Family

ID=44306157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007933A MX2012007933A (es) 2010-01-08 2011-01-07 Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.

Country Status (10)

Country Link
US (1) US20130072532A1 (enExample)
EP (1) EP2521544A4 (enExample)
JP (1) JP2013516482A (enExample)
CN (1) CN102753169A (enExample)
AU (1) AU2011204315A1 (enExample)
CA (1) CA2786598A1 (enExample)
MX (1) MX2012007933A (enExample)
NZ (2) NZ703808A (enExample)
RU (1) RU2012133969A (enExample)
WO (1) WO2011085162A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201604653TA (en) * 2011-12-11 2016-07-28 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
ES2765264T3 (es) * 2013-05-06 2020-06-08 Allergan Inc Agonistas alfa-adrenérgicos para el tratamiento de traumatismo tisular
RU2646512C2 (ru) * 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
RU2648817C2 (ru) * 2013-10-07 2018-03-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для лечения абстинентных синдромов с использованием неседативных трансдермальных композиций на основе дексмедетомидина
CN105764496B (zh) * 2013-10-07 2020-09-25 帝国制药美国公司 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
CA2924188C (en) * 2013-10-07 2018-12-18 Teikoku Pharma Usa, Inc. Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
CA3038354C (en) * 2016-10-31 2021-08-17 Teikoku Pharma Usa, Inc. Methods of managing pain using dexmedetomidine transdermal delivery devices
PT3562486T (pt) 2016-12-31 2024-06-12 Bioxcel Therapeutics Inc Uso de dexmedetomidina sublingual para o tratamento da agitação
CN107929234B (zh) * 2017-12-25 2021-07-23 温州医科大学附属第一医院 一种应用于烧伤创面修复的外用制剂膏体
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
WO2020176807A1 (en) 2019-02-27 2020-09-03 Vanderbilt University Methods of treating trigeminal nerve pain
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
MX2021012824A (es) 2019-05-01 2022-10-19 Clexio Biosciences Ltd Métodos para tratar el prurito.
JP7739256B2 (ja) 2019-07-19 2025-09-16 バイオエクセル セラピューティクス,インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
CN113577556A (zh) * 2021-08-01 2021-11-02 武汉左点科技有限公司 一种用于阴道康复治疗的生物反馈电刺激方法及装置
CN117582424A (zh) * 2022-08-17 2024-02-23 宜昌人福药业有限责任公司 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
US20030022926A1 (en) * 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production

Also Published As

Publication number Publication date
EP2521544A2 (en) 2012-11-14
NZ703808A (en) 2016-01-29
CA2786598A1 (en) 2011-07-14
US20130072532A1 (en) 2013-03-21
WO2011085162A2 (en) 2011-07-14
EP2521544A4 (en) 2013-08-21
JP2013516482A (ja) 2013-05-13
AU2011204315A1 (en) 2012-08-02
RU2012133969A (ru) 2014-02-20
CN102753169A (zh) 2012-10-24
NZ601195A (en) 2015-02-27
WO2011085162A3 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MX342951B (es) Composiciones terapeuticamente activas y su metodo de uso.
MX366318B (es) Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
EP4647076A3 (en) Therapeutically active compounds and their methods of use
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
GB201111485D0 (en) Drug composition and its use in therapy
IL235923A0 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
EP3054931A4 (en) Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
WO2009114703A3 (en) Combination therapy for the treatment of cancer
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
IL251543B (en) Use of gel compounds in the production of medicine to prevent or treat skin diseases
EP2897621A4 (en) COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES, PAIN AND FEVER, SKIN DISEASES, CANCER AND PRECULTURAL INJURIES
PH12012501389A1 (en) Hedgehog inhibitors
PH12013501163A1 (en) Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
EP3449917A3 (en) Tapentadol for preventing chronification of pain
DK2155179T3 (da) Axomadol til smertebehandling arthrose
MX366118B (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
HK1177894A (en) Topical transdermal dexmedetomidine compositions and methods of use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal